| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000016050 |
| Receipt No. | R000018654 |
| Official scientific title of the study | A clinical for evaluating the effect of L-citrulline and PDE5 inhibitor on erectile dysfunction and dysuria |
| Date of disclosure of the study information | 2014/12/25 |
| Last modified on | 2018/12/27 (Ver. 5) |
| Basic information | ||
| Official scientific title of the study | A clinical for evaluating the effect of L-citrulline and PDE5 inhibitor on erectile dysfunction and dysuria | |
| Title of the study (Brief title) | A clinical for evaluating the effect of L-citrulline on erectile dysfunction and dysuria
|
|
| Region |
|
|
| Condition | ||
| Condition | Benign Prostatic Hyperplasia | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the effect of L-citrulline and PDE5 inhibitor intake for 8weeks on the function of corpus cavernosum and dysuria |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Erectile function (IIEF,EHS) |
| Key secondary outcomes | IPSS,OABSS,frequency volume chart,UFM,residual urine,SEP2, SEP3, GAQ,VAS,blood biochemistry |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Intake of L-citruline for 8weeks | |
| Interventions/Control_2 | Intake of placebo for 8weeks | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male | |||
| Key inclusion criteria | 1.Subject aged from 45 to 75 years
2.Subject taking PDE5 inhibitor for 4weeks to treat Benign Prostatic Hyperplasia. 3.Subject classified IIEF score 8 to 25 4.Subject having sexual intercourse at least once a 8 week. |
|||
| Key exclusion criteria | 1.Subject receiving a medical treatment for serious renal, hepatic, cardio-vascular, respiratory, endocrine or metabolic disorders
2.Subject having a neurological disease 3.Subject having penile organic dysfunction 4.Subject having endocrine disease 5.Subject injecting insulin 6.Subject receiving hormone replacement therapy 7.Subject diagnosed psychogenic ED 8.Subject having the habit of taking a L-citrulline 9.Subject judged to be ineligible by the investigator for other reason |
|||
| Target sample size | 40 | |||
| Research contact person | |
| Name of lead principal investigator | Kazunori Kimura |
| Organization | Graduate School of Medical Sciences, Nagoya City University |
| Division name | Department of Clinical Pharmacy |
| Address | 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya |
| TEL | 052-851-5511 |
| kkimura@med.nagoya-cu.ac.jp | |
| Public contact | |
| Name of contact person | Kazunori Kimura |
| Organization | Graduate School of Medical Sciences, Nagoya City University |
| Division name | Department of Clinical Pharmacy |
| Address | 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya |
| TEL | 052-851-5511 |
| Homepage URL | |
| kkimura@med.nagoya-cu.ac.jp | |
| Sponsor | |
| Institute | Nagoya City University Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | KYOWA HAKKO BIO CO., LTD |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000018654 |